Migraine In Children clinical trials

Explore recruiting migraine in children clinical trials.

Recruiting migraine in children studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Migraine In Children trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

Finland, Spain, Italy, Germany, Netherlands, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4951002 Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age

Sweden, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Migraine In Children trials by city

Migraine In Children clinical trials

Recruiting migraine in children studies right now

Supraspinal Processing of Sensory Aspects of Pain

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

VICO-trial: Video Consultations in the Follow-up of Children With Functional Abdominal Pain Disorders

Association of Helicobacter Pylori Infection and Migraine

nVNS for the Prevention and Treatment of Primary Headache

Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Also recruiting in Europe

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

C4951002 Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age

Migraine In Children trials by city

Other conditions